Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1150 ARTÍCULOS , VIENDO DEL 901 AL 915

A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial

Vreugdenhil A, Cannell J, Davies A, Razay G.

Scand J Caring Sci. 2012 Mar;26(1):12-9. doi: 10.1111/j.1471-6712.2011.00895.x. Epub 2011 May 12.

[Validation of the Spanish version of the QoL-AD Scale in alzheimer disease patients, their carers, and health professionals]

Gómez-Gallego M, Gómez-Amor J, Gómez-García J.

Neurologia. 2012 Jan;27(1):4-10. doi: 10.1016/j.nrl.2011.03.006. Epub 2011 May 12.

Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease

Lehmann M, Koedam EL, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YA, Barkhof F, Wattjes MP, Scheltens P, Fox NC.

Neurobiol Aging. 2012 Mar;33(3):627.e1-627.e12. doi: 10.1016/j.neurobiolaging.2011.04.003. Epub 2011 May 18.

Morphometric characterization of Binswanger's disease: comparison with Alzheimer's disease

Shiino A, Akiguchi I, Watanabe T, Shirakashi Y, Nozaki K, Tooyama I, Inubushi T.

Eur J Radiol. 2012 Sep;81(9):2375-9. doi: 10.1016/j.ejrad.2011.05.031. Epub 2011 Jun 25.

The Fear of Alzheimer's Disease Scale: a new measure designed to assess anticipatory dementia in older adults

French SL, Floyd M, Wilkins S, Osato S.

Int J Geriatr Psychiatry. 2012 May;27(5):521-8. doi: 10.1002/gps.2747. Epub 2011 Jul 1.

Measuring health-related quality-of-life for Alzheimer's disease using the general public

Xie F, Oremus M, Gaebel K.

Qual Life Res. 2012 May;21(4):593-601. doi: 10.1007/s11136-011-9966-8. Epub 2011 Jul 9.

Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis

Dai L, Liu D, Guo H, Wang Y, Bai Y.

J Neurol. 2012 Mar;259(3):414-9. doi: 10.1007/s00415-011-6164-0. Epub 2011 Jul 12.

Do tocotrienols have potential as neuroprotective dietary factors?

Frank J, Chin XW, Schrader C, Eckert GP, Rimbach G.

Ageing Res Rev. 2012 Jan;11(1):163-80. doi: 10.1016/j.arr.2011.06.006. Epub 2011 Jul 7.

APP physiological and pathophysiological functions: insights from animal models

Guo Q, Wang Z, Li H, Wiese M, Zheng H.

Cell Res. 2012 Jan;22(1):78-89. doi: 10.1038/cr.2011.116. Epub 2011 Jul 19.

Validation of the Icelandic version of the Neuropsychiatric Inventory with Caregiver Distress (NPI-D)

Davidsdottir SR, Snaedal J, Karlsdottir G, Atladottir I, Hannesdottir K.

Nord J Psychiatry. 2012 Feb;66(1):26-32. doi: 10.3109/08039488.2011.593100. Epub 2011 Jul 20.

Misfolded proteins in Alzheimer's disease and type II diabetes

DeToma AS, Salamekh S, Ramamoorthy A, Lim MH.

Chem Soc Rev. 2012 Jan 21;41(2):608-21. doi: 10.1039/c1cs15112f. Epub 2011 Aug 4.

Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI

Holland D, McEvoy LK, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2012 Nov;33(11):2586-602. doi: 10.1002/hbm.21386. Epub 2011 Aug 9.

Complement receptor 1 (CR1) and Alzheimer's disease

Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J.

Immunobiology. 2012 Feb;217(2):244-50. doi: 10.1016/j.imbio.2011.07.017. Epub 2011 Jul 23.

Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection

Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, Drago F, Nicoletti F, Copani A.

Cell Tissue Res. 2012 Jan;347(1):291-301. doi: 10.1007/s00441-011-1230-6. Epub 2011 Aug 31.

'Clinical trials in Alzheimer's disease': immunotherapy approaches

Delrieu J, Ousset PJ, Caillaud C, Vellas B.

J Neurochem. 2012 Jan;120 Suppl 1:186-193. doi: 10.1111/j.1471-4159.2011.07458.x. Epub 2011 Nov 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias